Who are Cyclophosphamide-fludarabine-anti thymocyte globulin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclophosphamide-fludarabine-anti-thymocyte-globulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cyclophosphamide-fludarabine-anti thymocyte globulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cyclophosphamide-fludarabine-anti thymocyte globulin (Cyclophosphamide-fludarabine-anti thymocyte globulin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination / Immunosuppressive conditioning regimen. Area: Oncology / Hematology.

phase 3 Chemotherapy combination / Immunosuppressive conditioning regimen Oncology / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Cyclophosphamide-fludarabine-anti thymocyte globulin (Cyclophosphamide-fludarabine-anti thymocyte globulin) — Cooperative Study Group A for Hematology. This combination regimen uses cyclophosphamide and fludarabine to deplete immune cells, followed by anti-thymocyte globulin to further suppress T-cell mediated rejection, typically used as conditioning for hematopoietic stem cell transplantation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclophosphamide-fludarabine-anti thymocyte globulin TARGET	Cyclophosphamide-fludarabine-anti thymocyte globulin	Cooperative Study Group A for Hematology	phase 3	Chemotherapy combination / Immunosuppressive conditioning regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination / Immunosuppressive conditioning regimen class)

Cooperative Study Group A for Hematology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyclophosphamide-fludarabine-anti thymocyte globulin — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclophosphamide-fludarabine-anti-thymocyte-globulin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab